Diclofenac sodium transdermal patch - Hisamitsu Pharmaceuticals
Alternative Names: Diclofenac sodium transdermal patch; HP-3150; HP-5000; HSP3150Latest Information Update: 29 Aug 2022
At a glance
- Originator Hisamitsu Pharmaceutical
- Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Back pain; Cancer pain; Cervicobrachial syndrome; Pain; Periarthritis; Tenosynovitis
Most Recent Events
- 25 Jul 2022 Noven Pharmaceuticals completes a phase III trial in Pain in USA (Transdermal) (NCT04683627)
- 11 Mar 2022 Noven Pharmaceuticals completes a phase I trial in Pain (In volunteers) in USA (Topical, Patch) (NCT04882319)
- 11 May 2021 Noven Pharmaceuticals initiates enrolment in a phase I trial for Pain (In volunteers) in USA (Topical, Patch) in May 2021 (NCT04882319)